Legal Opinion
In Re Huai-Hung Kao
Court of Appeals for the Federal Circuit
Decided May 13, 2011No. 2010-1307, 2010-1308, 2010-1309PublishedCited by 66 opinions
1Opinion of the Court
LINN, Circuit Judge.
Endo Pharmaceuticals, Inc. (“Endo”) is the assignee of three patent applications related to controlled-release tablets containing the opioid narcotic oxymorphone. The Board of Patent Appeals and Interferences (“the Board”), in separate appeals, affirmed the rejection of the claims of each application as obvious, and Endo has separately appealed each decision to this court.
The Board affirmed the rejection of all pending claims of United States Patent Application No. 11/680,432 (“the '432 Application”), United States Patent Application No. 12/167,859 (“the '859…
2Cases cited26 opinions
- Consolidated Edison Co. v. National Labor Relations BoardSupreme Court of the United States · 1938
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Stratoflex, Inc. v. Aeroquip CorporationCourt of Appeals for the Federal Circuit · 1983
- In Re Robert J. Gartside and Richard C. NortonCourt of Appeals for the Federal Circuit · 2000
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
21 more not listed; retrieve them via the Exa API.
3Cited by66 opinions
- Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.Court of Appeals for the Federal Circuit · 2014
- Novartis AG v. Torrent Pharmaceuticals Ltd.Court of Appeals for the Federal Circuit · 2017
- Rambus Inc. v. ReaCourt of Appeals for the Federal Circuit · 2013
- Santarus, Inc. v. Par Pharmaceutical, Inc.Court of Appeals for the Federal Circuit · 2012
- Kennametal, Inc. v. Ingersoll Cutting Tool CompanyCourt of Appeals for the Federal Circuit · 2015
61 more not listed; retrieve them via the Exa API.